摘要
替莫唑胺(Temozolomide,TMZ)作为一种新型烷化剂药物对各种实体性肿瘤有着明显的抗肿瘤作用,其中在胶质瘤的治疗中,其作为一线用药更是有着不可取代的地位。替莫唑胺能够对基因组DNA造成损伤,从而杀伤肿瘤细胞,但是这种损伤能被O^6-甲基鸟嘌呤-DNA甲基转移酶(O^6-methylguanine DNA methyltranferase,MGMT)所修复,从而造成化疗耐药,直接影响替莫唑胺的杀伤肿瘤的作用。本综述主要叙述了近期在本领域中最新的针对MGMT增敏替莫唑胺的研究。
Alkylating agents such as temozolomide（TMZ）are effective anticancer drugs for treating a variety of solid tumors. What＇s more,it has an irreplaceable position in glioma treatment as a first-line drugs.TMZ exerts its effects mainly via a cytotoxic DNA lesion. Unfortunately,this damage may be repaired by the DNA repair enzyme O^6-methylguanine DNA methyltransferase（MGMT）, a key player in the resistance of cancers to TMZ. In this review, we provide an overview of recent advances about improving the killing of tumor cells by TMZ, with inhibition of MGMT being the most promising.
出处
《中国现代医生》
2016年第6期165-168,共4页
China Modern Doctor
